Inhaled Edoxaban dry powder inhaler formulations: Development, characterization and their effects on the coagulopathy associated with COVID-19 infection
Herein, we demonstrated the development and characterization of a dry powder inhaler
(DPI) formulation of edoxaban (EDX); and investigated the in-vitro anticoagulation effect for …
(DPI) formulation of edoxaban (EDX); and investigated the in-vitro anticoagulation effect for …
[HTML][HTML] Spectrophotometric, chromatographic and bioanalysis of selected recently approved drugs from 2015–2020 to treat cardiovascular diseases: an analytical …
S Gharge, R Koli, S Gudasi, SI Hiremath - Bulletin of the National …, 2023 - Springer
Abstract Background Heart Study has been operating for more than 40 years, and
throughout that time it has found a number of risk variables that interact negatively to have …
throughout that time it has found a number of risk variables that interact negatively to have …
[HTML][HTML] Rapid assay for the therapeutic drug monitoring of edoxaban
Edoxaban is a direct oral anticoagulant (DOAC) that has been recently indicated for the
treatment of pulmonary embolism (PE) in SARS-CoV-2 infections. Due to its …
treatment of pulmonary embolism (PE) in SARS-CoV-2 infections. Due to its …
A highly sensitive and selective electrochemical sensing probe for detection of Edoxaban anticoagulant drug residue in environmental water and drug formulations
H Alwael, MM Dabi, EA Bahaidarah… - International Journal …, 2024 - Taylor & Francis
Anticoagulant drugs currently play a crucial role in preventing severe deep vein thrombosis,
heart attacks, heart valve diseases and contribute to the regulation of blood flow. Thus, the …
heart attacks, heart valve diseases and contribute to the regulation of blood flow. Thus, the …
[PDF][PDF] Analytical method development and validation of edoxaban in bulk and pharmaceutical dosage form by rp-hplc
SD Banda, MJ Naim - J Tianjin Univ Sci Technol, 2022 - tianjindaxuexuebao.com
RP-HPLC method for estimation of Edoxaban in bulk and pharmaceutical dosage forms was
obtained with Hypersil ODS C18 (100mm× 4.6 mm, 5µm particle size); Shimadzu LC-20AT …
obtained with Hypersil ODS C18 (100mm× 4.6 mm, 5µm particle size); Shimadzu LC-20AT …
Liquid chromatography separation and identification of new oxidative degradation impurity in edoxaban tosylate hydrate drug substance by using liquid …
C Alluri, GVR Sharma - European Journal of Mass …, 2023 - journals.sagepub.com
Edoxaban is an anti-coagulant medication and a director factor Xa inhibitor. A novel reverse
phase liquid chromatography–mass spectrometry compatible method developed for …
phase liquid chromatography–mass spectrometry compatible method developed for …
[PDF][PDF] Validated Stability Indicating HPTLC Method Development for Rivaroxaban in Tablets
H Nimje, M Magar, P Kamble, N Rongali - Ind. J. Pharm. Edu. Res, 2024 - ijper.org
Objectives: The present goal of this analytical study is to develop a simple, reliable, sensitive
and robust method that can identify Rivaroxaban (RVB) by using high performance thin …
and robust method that can identify Rivaroxaban (RVB) by using high performance thin …
[PDF][PDF] Design of Experiment Mediated Development of Stability Indicating High Performance Thin Layer Chromatography Method Invoking Failure Mode Effect …
VB Mistry, HB Patel, PP Dedhiya, KB Bodiwala… - INDIAN JOURNAL OF …, 2022 - ijper.org
Aim: Development of stability indicating high performance thin layer chromatographic
method for quantification of edoxaban tosylate monohydrate in its pharmaceutical dosage …
method for quantification of edoxaban tosylate monohydrate in its pharmaceutical dosage …